Hunt­ing more R&D deals, Ipsen is ham­mer­ing out a $460M sale of con­sumer ops while cut­ting costs

These days, con­sumer health di­vi­sions rep­re­sent a con­ve­nient source of cash as phar­ma play­ers dou­ble down on their R&D op­er­a­tions and hunt new deals. GSK and J&J have both rolled the dice. And Ipsen jumped in­to this game to­day, of­fer­ing a scaled-down ver­sion of this gam­bit for the $8 bil­lion French phar­ma play­er.

The com­pa­ny re­port­ed that it’s ne­go­ti­at­ing with May­oly Spindler to di­vest its rel­a­tive­ly bite-sized con­sumer di­vi­sion for $460 mil­lion, with €350 mil­lion up­front and an­oth­er €50 mil­lion on the back end as an earn-out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER